News Sentiment

ZYBT sentiment intelligence

Zhengye Biotechnology Holding Limited Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 43 Balanced news tone 36 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 0.75 Week of 19 Jun 2026
Weighted tone 43/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-9.7% over one week, -13.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Zhengye Biotechnology Holding Ltd (ZYBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -9.7% Price reacting lower
Trend fit Trend inactive -13.7% over four weeks
Fair value -80.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 15
Negative 15

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 10
Stock Titan 4
Quiver Quantitative 3
Market source 2
GlobeNewswire 2
TipRanks 2
Investing.com UK 1
Investing.com Australia 1

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 6
Regulatory and legal 3
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 36
TradingKey Direct company coverage

Zhengye Biotechnology Holding Ltd (ZYBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Zhengye Biotechnology Holding Ltd (ZYBT), focusing on its support, resistance, indicators, and moving averages. According to the analysis, ZYBT currently exhibits a strong "Sell" signal based on various technical indicators and moving

Tone
Negative 20/100
Event
Market update
Published
18 Jun 2026 03:39
Source
TradingKey
TradingKey Direct company coverage

Zhengye Biotechnology Holding Ltd (ZYBT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Zhengye Biotechnology Holding Ltd (ZYBT) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years and shows no record of stock splits. The page also inc

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 12:10
Source
TradingKey
TradingKey Direct company coverage

Zhengye Biotechnology Holding Ltd (ZYBT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Zhengye Biotechnology Holding Ltd (ZYBT), noting that relevant data for P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The stock is currently trading at $0.809, down 3.98%, with a market cap of 38.34M.

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 11:10
Source
TradingKey
TradingKey Direct company coverage

Zhengye Biotechnology Holding Ltd (ZYBT) Institutional Confidence

The article details the institutional confidence in Zhengye Biotechnology Holding Ltd (ZYBT) by listing its institutional shareholders and their recent activity. Key shareholders include Han (Zhenfa), XTX Markets LLC, Winton Capital Management Ltd., and Citadel Advisors LLC, with

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 10:10
Source
TradingKey
TradingKey Direct company coverage

Zhengye Biotechnology Holding Ltd

This article provides a detailed revenue breakdown for Zhengye Biotechnology Holding Ltd (ZYBT) for fiscal year 2024. It highlights the company's primary revenue sources, with swine vaccines accounting for the largest proportion at 84.67%, followed by poultry vaccines and other v

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 09:10
Source
TradingKey
Investing.com UK Direct company coverage

Zhengye Biotechnology receives Nasdaq bid price deficiency notice

Zhengye Biotechnology (NASDAQ:ZYBT) has received a notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share, with its stock trading significantly lower. The company has 180 calendar days to regain compliance, potentially considering a reverse sh

Tone
Negative 19/100
Event
Market update
Published
05 Jun 2026 21:39
Source
Investing.com UK
Investing.com Australia Direct company coverage

Zhengye Biotechnology receives Nasdaq bid price deficiency notice By Investing.com

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) has received a Nasdaq deficiency notice for failing to meet the minimum bid price requirement of $1.00 per share. The company has 180 days to regain compliance by achieving a closing bid price of at least $1.00 for ten consecuti

Tone
Negative 19/100
Event
Market update
Published
05 Jun 2026 19:09
Source
Investing.com Australia
BriefGlance Direct company coverage

Zhengye Biotech's Nasdaq Lifeline: A 180-Day Race Against Financial Reality

Zhengye Biotech (Nasdaq: ZYBT) has received a Nasdaq deficiency notice due to its stock failing to maintain the $1.00 minimum bid price, giving it until November 25, 2026, to regain compliance. The company faces significant financial challenges, including an 87% stock drop, a 37.

Tone
Negative 28/100
Event
Market update
Published
05 Jun 2026 09:11
Source
BriefGlance
Stock Titan Direct company coverage

Zhengye Biotech has 6 months to lift stock back above $1

Zhengye Biotechnology (ZYBT) received a Nasdaq notice on May 29, 2026, for failing to meet the US$1.00 minimum bid price requirement for 30 consecutive business days. The company has until November 25, 2026, to regain compliance by having its stock close at or above US$1.00 for a

Tone
Negative 34/100
Event
Market update
Published
04 Jun 2026 20:05
Source
Stock Titan
Market source Direct company coverage

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Zhengye Biotechnology Holding Limited (ZYBT) announced it received a Nasdaq notification for not meeting the minimum bid price requirement of US$1.00 per share. The company has 180 calendar days, until November 25, 2026, to regain compliance by maintaining a closing bid price of

Tone
Negative 29/100
Event
Market update
Published
04 Jun 2026 20:05
Source
Market source
ChartMill Direct company coverage

ZYBT Stock Price, Quote & Chart | ZHENGYE BIOTECHNOLOGY-A (NASDAQ:ZYBT)

This article provides a detailed overview of ZHENGYE BIOTECHNOLOGY-A (NASDAQ: ZYBT) stock, including its current price, performance metrics, and key statistics like market cap and EPS. It also presents ChartMill's technical and fundamental analysis ratings, highlighting the compa

Tone
Negative 34/100
Event
Earnings
Published
17 May 2026 18:39
Source
ChartMill
TradingKey Direct company coverage

TradingKey

This page provides an overview of Zhengye Biotechnology Holding Ltd (ZYBT) on TradingKey. It details the stock's current price, market cap, and offers sections for financials, discussions, and analysis. The content also highlights TradingKey's various tools, news, and educational

Tone
Positive 64/100
Event
Market update
Published
12 May 2026 02:39
Source
TradingKey
Market source Direct company coverage

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Zhengye Biotechnology Holding Limited announced its financial results for fiscal year 2025, reporting a net loss of RMB83.0 million, compared to a net income of RMB13.5 million in 2024. This downturn was primarily due to a challenging hog market and government policies impacting

Tone
Negative 30/100
Event
Earnings
Published
29 Apr 2026 20:10
Source
Market source
Stock Titan Direct company coverage

China hog slump hits Zhengye as vaccine maker posts annual loss

Zhengye Biotechnology (Nasdaq: ZYBT) announced a 37.6% decrease in total revenue for fiscal year 2025, reaching RMB116.4 million ($16.6 million), and reported a net loss of RMB83.0 million ($11.9 million). This decline was primarily attributed to a downturn in China's hog market

Tone
Negative 32/100
Event
Earnings
Published
28 Apr 2026 20:09
Source
Stock Titan
MEXC Exchange Direct company coverage

ZYBT Price Today: Zhengye Biotechnology Holding Limited Stock Price, Quote & Chart | MEXC

Zhengye Biotechnology Holding Limited (ZYBT) is currently trading at $0.91, down from its previous close of $0.92. The stock has seen a +7.06% return over the past month but a significant -93.57% decline over the last 12 months, indicating weak performance. The company specialize

Tone
Negative 35/100
Event
Market update
Published
25 Apr 2026 16:10
Source
MEXC Exchange
Quiver Quantitative Direct company coverage

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

Zhengye Biotechnology Holding Limited has implemented a dual-class share structure, effective April 7, 2026, introducing Class A and Class B ordinary shares with different voting rights. This restructuring, approved by shareholders, aims to enhance corporate governance and capita

Tone
Neutral 50/100
Event
Market update
Published
06 Apr 2026 13:30
Source
Quiver Quantitative
GlobeNewswire Direct company coverage

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced the implementation of a dual-class share structure, effective April 7, 2026. The new structure introduces Class A ordinary shares with one vote each and Class B ordinary shares with twenty votes each, with Class B sha

Tone
Neutral 50/100
Event
Market update
Published
06 Apr 2026 13:10
Source
GlobeNewswire
Stock Titan Direct company coverage

Zhengye's new share classes give some holders 20 votes each

Zhengye Biotechnology Holding Limited (ZYBT) has implemented a dual-class share structure, effective April 7, 2026, following shareholder approval on March 24, 2026. This reclassifies the authorized capital into 1.9 billion Class A ordinary shares, each carrying one vote, and 100

Tone
Neutral 50/100
Event
Regulatory and legal
Published
06 Apr 2026 13:10
Source
Stock Titan
TipRanks Direct company coverage

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

Zhengye Biotechnology Holding Ltd. (ZYBT) held its Annual General Meeting on March 24, 2026, where shareholders approved significant changes to the company's governance and share structure. These changes involved the election of new directors, re-election of existing ones, a shar

Tone
Neutral 50/100
Event
Market update
Published
25 Mar 2026 10:39
Source
TipRanks
Moomoo Direct company coverage

$Zhengye Biotechnology (ZYBT.US)$ still hodl some for moon

A moomoo Community member, MsNoFomoTrade, shared a post regarding Zhengye Biotechnology (ZYBT.US), indicating they are still holding the stock with an optimistic outlook for future gains. The brief post is part of a discussion within the moomoo community platform.

Tone
Positive 66/100
Event
Guidance
Published
23 Mar 2026 15:39
Source
Moomoo
www.marketscreener.com Direct company coverage

Zhengye Biotechnology Holding Limited Announces Resignation of Wenbin Wang as Independent Director, Member of Committees, and Chairperson of the Compensation Committee, Effective February 18, 2026

Zhengye Biotechnology Holding Limited announced that Wenbin Wang resigned as an independent director, a member of the Audit, Compensation, and Nominating and Corporate Governance Committees, and chairperson of the Compensation Committee, effective February 18, 2026. Wang's resign

Tone
Neutral 50/100
Event
Market update
Published
24 Feb 2026 10:51
Source
www.marketscreener.com
TipRanks Direct company coverage

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

Zhengye Biotechnology Holding Ltd. announced that independent director Wenbin Wang resigned on February 18, 2026, due to personal reasons, leaving the company temporarily non-compliant with Nasdaq's majority independent director rule. The company plans to appoint a replacement at

Tone
Negative 38/100
Event
Market update
Published
23 Feb 2026 21:30
Source
TipRanks
Intellectia AI Direct company coverage

ZYBT Should I Buy

An analysis of Zhengye Biotechnology Holding Ltd (ZYBT) indicates it is not a strong buy for long-term beginner investors. Technical indicators show a bearish trend with weakening momentum and no positive catalysts or significant trading signals. The stock is trading below its pi

Tone
Negative 38/100
Event
Market update
Published
23 Feb 2026 11:51
Source
Intellectia AI
GlobeNewswire Direct company coverage

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

Zhengye Biotechnology Holding Limited's Chairman, Zhenfa Han, issued a letter to shareholders detailing the company's achievements in 2025 and strategic priorities for 2026. The letter highlights R&D innovation, regulatory milestones, international market expansion, enhanced prod

Tone
Positive 82/100
Event
Regulatory and legal
Published
10 Feb 2026 13:58
Source
GlobeNewswire